The Danish publicly listed biopharmaceutical company NeuroSearch A/S has signed a conditional agreement to acquire A. Carlsson Research AB – one of Sweden’s leading biopharmaceutical companies within discovery and development of drugs for the treatment of diseases in the central nervous system (CNS). The agreed consideration amounts to SEK 875 million whereof SEK 250 million is to be paid upfront and SEK 625 million is to be paid in connection with the successful attainment of agreed development milestones.
“Since inception, we have proven our ability to efficiently generate truly novel candidate drugs for the treatment of CNS disorders”, said Nicholas Waters, CEO Carlsson Research AB. “As part of NeuroSearch, Carlsson Research programs will be added significant scientific resources and the financial strength necessary to fully exploit the medical, and thereby commercial, potential of our products, which is of great interest for all Carlsson Research stakeholders.”

“Carlsson...